TMO Stock - Thermo Fisher Scientific Inc.
Unlock GoAI Insights for TMO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B |
| Gross Profit | $17.73B | $17.19B | $19.01B | $19.63B | $16.03B |
| Gross Margin | 41.3% | 40.1% | 42.3% | 50.1% | 49.7% |
| Operating Income | $7.66B | $7.45B | $8.53B | $10.32B | $7.90B |
| Net Income | $6.33B | $6.00B | $6.95B | $7.72B | $6.38B |
| Net Margin | 14.8% | 14.0% | 15.5% | 19.7% | 19.8% |
| EPS | $16.58 | $15.53 | $17.73 | $19.61 | $16.10 |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | Citigroup | Upgrade | Buy | $660 |
| December 9th 2025 | Goldman | Initiation | Buy | $685 |
| December 8th 2025 | KeyBanc Capital Markets | Upgrade | Overweight | $750 |
| December 2nd 2025 | Morgan Stanley | Resumed | Overweight | $670 |
| December 1st 2025 | HSBC Securities | Upgrade | Buy | $670 |
| September 11th 2025 | Barclays | Upgrade | Overweight | $550 |
| August 19th 2025 | William Blair | Initiation | Outperform | - |
| July 24th 2025 | HSBC Securities | Downgrade | Hold | $510 |
| July 11th 2025 | Scotiabank | Upgrade | Sector Outperform | $590 |
| July 9th 2025 | UBS | Downgrade | Neutral | $460 |
| January 10th 2025 | Bernstein | Upgrade | Outperform | $630 |
| December 23rd 2024 | Scotiabank | Initiation | Sector Perform | - |
| October 14th 2024 | Redburn Atlantic | Initiation | Buy | - |
| October 1st 2024 | Stephens | Initiation | Overweight | $680 |
| August 28th 2024 | Wells Fargo | Initiation | Overweight | $670 |
Earnings History & Surprises
TMOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 21, 2026 | — | — | — | — |
Q1 2026 | Jan 29, 2026 | $6.44 | — | — | — |
Q4 2025 | Oct 22, 2025 | $5.50 | $5.79 | +5.3% | ✓ BEAT |
Q3 2025 | Jul 23, 2025 | $5.23 | $5.36 | +2.5% | ✓ BEAT |
Q2 2025 | Apr 23, 2025 | $5.10 | $5.15 | +1.0% | ✓ BEAT |
Q1 2025 | Jan 30, 2025 | $5.94 | $6.10 | +2.7% | ✓ BEAT |
Q4 2024 | Oct 23, 2024 | $5.25 | $5.28 | +0.6% | ✓ BEAT |
Q3 2024 | Jul 24, 2024 | $5.12 | $5.37 | +4.9% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $4.71 | $5.11 | +8.5% | ✓ BEAT |
Q1 2024 | Jan 31, 2024 | $5.64 | $5.67 | +0.5% | ✓ BEAT |
Q4 2023 | Oct 25, 2023 | $5.61 | $5.69 | +1.4% | ✓ BEAT |
Q3 2023 | Jul 26, 2023 | $5.43 | $5.15 | -5.2% | ✗ MISS |
Q2 2023 | Apr 26, 2023 | $4.95 | $5.03 | +1.6% | ✓ BEAT |
Q1 2023 | Feb 1, 2023 | $5.19 | $5.40 | +4.0% | ✓ BEAT |
Q4 2022 | Oct 26, 2022 | $4.78 | $5.08 | +6.3% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $4.99 | $5.51 | +10.4% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $6.18 | $7.25 | +17.3% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $5.22 | $6.54 | +25.3% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $4.67 | $5.76 | +23.3% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $5.44 | $5.60 | +2.9% | ✓ BEAT |
Latest News
Wells Fargo Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $675
📈 PositiveCitigroup Upgrades Thermo Fisher Scientific to Buy, Raises Price Target to $660
📈 PositiveGoldman Sachs Initiates Coverage On Thermo Fisher Scientific with Buy Rating, Announces Price Target of $685
📈 PositiveKeybanc Upgrades Thermo Fisher Scientific to Overweight, Announces $750 Price Target
📈 PositiveGeninCode PLC Partners With Thermo Fisher Scientific For Cardio InCode-Score Manufacturing And Distribution In US And EMEA
📈 PositiveThermo Fisher Expands Bioprocessing Network Across Asia To Boost Regional Biopharma Innovation
📈 PositiveMorgan Stanley Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $670
📈 PositiveHSBC Upgrades Thermo Fisher Scientific to Buy, Raises Price Target to $670
📈 PositiveReported Earlier, Thermo Fisher Scientific Announced That It Has Priced An Offering Of EUR 2.1 Billion Aggregate Principal Amount Of The Following Euro-denominated Notes
➖ NeutralLive On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: Thermo Fisher Scientific, Agilent Technologies"
📈 PositiveCNBC Halftime Report Final Trades: UnitedHealth Group, Thermo Fisher Scientific, Monster Beverage, iShares U.S. Healthcare ETF
➖ NeutralThermo Fisher Scientific Receives 510(k) Clearance For EXENT Analyser And Immunoglobulin Isotypes Assay
📈 PositiveThermo Fisher Scientific Announces $5B Buyback Plan
📈 PositiveArgus Research Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $610
📈 PositiveThermo Fisher To Buy Clario For $8.9B In Cash, Plus Up To $400M In Performance-Based Payouts
📈 PositiveMorgan Stanley Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $656
📈 PositiveUBS Maintains Neutral on Thermo Fisher Scientific, Raises Price Target to $590
➖ NeutralTD Cowen Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $654
📈 PositiveWells Fargo Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $635
📈 PositiveBarclays Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $625
📈 PositiveFrequently Asked Questions about TMO
What is TMO's current stock price?
What is the analyst price target for TMO?
What sector is Thermo Fisher Scientific Inc. in?
What is TMO's market cap?
Does TMO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TMO for comparison